Additionally, the 36-month beta value for RXST is 1.20. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RXST is 31.24M and currently, short sellers hold a 4.70% ratio of that float. The average trading volume of RXST on May 02, 2024 was 400.72K shares.
RXST) stock’s latest price update
RxSight Inc (NASDAQ: RXST) has experienced a rise in its stock price by 8.77 compared to its previous closing price of 52.13. However, the company has seen a gain of 7.31% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-22 that ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RXST’s Market Performance
RxSight Inc (RXST) has seen a 7.31% rise in stock performance for the week, with a 12.46% gain in the past month and a 24.59% surge in the past quarter. The volatility ratio for the week is 4.52%, and the volatility levels for the past 30 days are at 5.00% for RXST. The simple moving average for the past 20 days is 6.29% for RXST’s stock, with a 48.90% simple moving average for the past 200 days.
Analysts’ Opinion of RXST
Many brokerage firms have already submitted their reports for RXST stocks, with Wells Fargo repeating the rating for RXST by listing it as a “Overweight.” The predicted price for RXST in the upcoming period, according to Wells Fargo is $42 based on the research report published on December 13, 2023 of the previous year 2023.
Stifel, on the other hand, stated in their research note that they expect to see RXST reach a price target of $40. The rating they have provided for RXST stocks is “Buy” according to the report published on December 12th, 2023.
Morgan Stanley gave a rating of “Overweight” to RXST, setting the target price at $36 in the report published on December 04th of the previous year.
RXST Trading at 7.87% from the 50-Day Moving Average
After a stumble in the market that brought RXST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.59% of loss for the given period.
Volatility was left at 5.00%, however, over the last 30 days, the volatility rate increased by 4.52%, as shares surge +10.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.56% upper at present.
During the last 5 trading sessions, RXST rose by +7.31%, which changed the moving average for the period of 200-days by +73.02% in comparison to the 20-day moving average, which settled at $53.62. In addition, RxSight Inc saw 40.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXST starting from Thunen Shelley B, who sale 20,000 shares at the price of $49.90 back on Apr 01 ’24. After this action, Thunen Shelley B now owns 8,402 shares of RxSight Inc, valued at $997,946 using the latest closing price.
Thunen Shelley B, the Chief Financial Officer of RxSight Inc, sale 10,000 shares at $56.37 during a trade that took place back on Mar 01 ’24, which means that Thunen Shelley B is holding 13,691 shares at $563,726 based on the most recent closing price.
Stock Fundamentals for RXST
Current profitability levels for the company are sitting at:
- -0.51 for the present operating margin
- 0.55 for the gross margin
The net margin for RxSight Inc stands at -0.51. The total capital return value is set at -0.31. Equity return is now at value -38.85, with -29.22 for asset returns.
Based on RxSight Inc (RXST), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -14.34. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -17.58.
Currently, EBITDA for the company is -45.84 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 21.54. The receivables turnover for the company is 4.81for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.06.
Conclusion
In conclusion, RxSight Inc (RXST) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
